title: Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
abstract: Clinical studies indicate that selective serotonin-reuptake inhibitors (SSRIs) may decrease alcohol intake and craving in particular subgroups of alcoholics. The aim of the present study was to compare the behavioral profile of various SSRIs in alcohol-preferring cAA rats, a genetic model of alcoholism. The effects of acute IP administration of fluoxetine (doses in mg/kg 1-10), citalopram (3-30), fluvoxamine (3-30) and paroxetine (1-10) on ethanol (EtOH) intake and preference, as well as food and total fluid intake, were determined in a 12-h access, water vs. 10% v/v EtOH two-bottle choice paradigm. Each compound reduced EtOH intake [Minimal Effective Doses (MEDs) 5, 10, 30 and 1 mg/kg for fluoxetine, citalopram, fluvoxamine, and paroxetine, respectively]. The degree of selectivity, that is, the extent to which reductions in EtOH intake could be separated from reductions in food and/or total fluid intake varied across the compounds. Thus, whereas EtOH intake was more markedly affected than food intake by fluoxetine, both parameters were equally affected by citalopram, and food intake was more markedly affected than EtOH intake by fluvoxamine and paroxetine. The anti-alcohol effect also differed with respect to specificity, that is, the degree to which effects on EtOH intake coincided with effects on EtOH preference. Whereas fluoxetine showed the highest level of specificity, followed by citalopram and fluvoxamine, the effect of paroxetine was nonspecific. The observed variation in the degree of selectivity and specificity of the anti-alcohol effect of SSRIs suggests that reductions in EtOH intake are not merely a consequence of a general suppressive effect on consummatory behavior. It is hypothesized that differences between the behavioral profiles of these compounds reflect a differential involvement of 5-HT receptor subtypes.
authors.affiliation: CNS Research, Bayer AG, Cologne, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Maurel
authors.forename: J
authors.initials: J
authors.lastname: De Vry
authors.forename: R
authors.initials: R
authors.lastname: Schreiber
mesh_terms: D000428:Alcohol Drinking; D000437:Alcoholism; D000818:Animals; D015283:Citalopram / Q000494:pharmacology*; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology*; D016666:Fluvoxamine / Q000494:pharmacology*; D005518:Food Preferences; D008297:Male; D017374:Paroxetine / Q000494:pharmacology*; D051381:Rats; D011922:Rats, Mutant Strains; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology
chemical_list: D015283:Citalopram; D000431:Ethanol; D005473:Fluoxetine; D016666:Fluvoxamine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors